FOSUN PHARMA (02196) announced that to further enhance its corporate governance structure, establish and improve the group's long-term incentive mechanisms, attract and retain outstanding talent, and fully mobilize the enthusiasm of the company's executive directors, employee directors, senior management personnel, and group employees, the company aims to effectively align shareholder interests, corporate interests, and the personal interests of the group's core team members. This initiative encourages all parties to focus collectively on the group's long-term development and work together toward common goals while fully protecting shareholder interests.

The company has formulated a draft 2025 A-Share Stock Option Incentive Plan. Under this plan, the maximum number of A-share options that can be granted is 5.7261 million units, corresponding to a maximum of 5.7261 million A-shares. These figures represent approximately 0.2144% of the company's total share capital and 0.2729% of the total A-shares (excluding A-share treasury stock), respectively.

The initial grant under this plan will target no more than 201 individuals as incentive recipients. The exercise price for the A-share options involved in the initial grant is set at 27.93 yuan per share.